FBC
STRO icon

Fairfield, Bush & Co’s Sutro Biopharma STRO Stock Holding History

Fairfield, Bush & Co’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200
Closed -$9.3K – 448
2023
Q2 		$9.3K Buy
+200
New +$9.96K ﹤0.01% 331
2022
Q3 		– Sell
-200
Closed -$10K – 414
2022
Q2 		$10K Buy
+200
New +$11.2K 0.01% 303

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fairfield, Bush & Co's STRO Position: Q3 2023 in Review

Fairfield, Bush & Co sold out of Sutro Biopharma (STRO) in Q3 2023, closing a stake of 200 shares — an estimated $9.3K sold.

Fairfield, Bush & Co first reported a position in STRO in Q2 2022 and held it in 2 quarters. The position peaked at $10K in Q2 2022. 108 funds tracked by Wall St. Rank hold STRO as of Q3 2023.

  • Fairfield, Bush & Co reported no remaining Sutro Biopharma position as of Q3 2023 after selling out during the quarter.
  • Fairfield, Bush & Co sold 200 Sutro Biopharma shares in Q3 2023, an estimated $9.3K.
  • Fairfield, Bush & Co first reported a position in Sutro Biopharma in Q2 2022 and held it in 2 quarters.
  • Fairfield, Bush & Co's Sutro Biopharma position peaked at $10K in Q2 2022.
  • 108 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2023.

Based on Fairfield, Bush & Co's 13F filing for Q3 2023, filed 15 Nov 2023.